Navigation Links
Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Date:4/8/2008

SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer announced today that it has entered into an agreement with Monogram Biosciences, Inc., under which Monogram will evaluate selected Raven monoclonal antibodies for use with its VeraTag(TM) technology for diagnosis of cancer.

"Raven's extensive library of antibody candidates that bind to antigens present at high levels on tumor tissue can be developed as therapeutic and diagnostic antibodies," stated George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies. "Through our collaboration with Monogram we hope ultimately to accelerate the development of targeted oncology therapeutics."

The Raven technology platform has generated well-characterized, high-affinity monoclonal antibodies to proteins on the cell surface that can be used to quickly identify and validate targets. The platform has delivered an extensive library of antibodies targeting novel and recognized antigens. Raven is initially focusing on antibody-based therapeutics targeting lung, colon, pancreatic, prostate, breast, and ovarian cancer.

Monogram Biosciences' VeraTag(TM) technology can accelerate the development of targeted therapeutics, improve clinical trial design and results, clarify and individualize the selection of medications, and optimize outcomes for patients with cancer and other serious diseases.

About Raven biotechnologies

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast and ovarian cancer.


'/>"/>
SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
3. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
7. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
8. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
9. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
10. VaxGen and Raven Terminate Merger Agreement
11. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016 According to ... by Products (Consumable, Instruments, Automated Cell Expansion System), ... Stem Cell Research, Cancer, and Cell-Based Research), End-users ... - Global Revenue, Trends, Growth, Share, Size and ... the global cell expansion market is expected to ...
(Date:12/5/2016)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... Safety Monitoring Board (DSMB) for the Company,s Phase ... patients has completed a second planned safety review ... planned without any modifications. The DSMB reviewed available ... efficacy concerns were identified. The DSMB will conduct ...
(Date:12/5/2016)... , Dec. 5, 2016  Eisai Inc. ... open-label two-year study of rufinamide, which were presented ... Epilepsy Society (AES) held from December 2-6 in ... final two-year safety, tolerability and cognitive data showed ... experienced similar safety and tolerability profiles, cognitive development ...
(Date:12/5/2016)... 2016 The U.S. Biotechnology industry ... billion of revenue and some $890 billion of total ... global biopharmaceuticals, and this figure is expected to exceed ... up these four equities for assessment: Northwest Biotherapeutics Inc. ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... Paris Police Prefecture ... solution to ensure the safety of people and operations in ... major tournament Teleste, an international technology group specialised ... today that its video security solution will be utilised by ... public safety across the country. The system roll-out is scheduled ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):